Laboratorios Rovi : PE interest is for real, we do not rule out a bid competition ‘à la Applus’
>Rovi has received five non-binding offers for its CDMO business - Earlier this year Rovi announced an assessment process to evaluate strategic alternatives to put in value its CDMO assets. Yesterday, the Spanish press leaked that Antin, Cinven, CVC, KKR and Permira have filed non-binding bids and are now in the middle of a due diligence process to produce binding offers which will be around the € 3.5bn mark. Soon after, the company confirmed, via a regulatory filing,...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.